President Trump’s September 18, 2026, Oval Office announcement expanded the administration’s Medicaid GENEROUS model, confirming all 50 states’ participation in Most Favored Nation drug pricing that aligns Medicaid payments for select prescription drugs with prices in peer nations. The rollout builds on earlier manufacturer agreements covering a large share of the branded market and follows prior MFN deals. Trump highlighted projected state savings for reinvestment in healthcare while noting the timing ahead of November midterms. Senior officials including HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Mehmet Oz joined Republican governors at the event. Traders are assessing which specific policy claims, savings figures, or political references the president emphasized during the remarks, given the announcement’s focus on price transparency and state-level implementation.